Literature DB >> 21961530

A high throughput in vitro mrp2 assay to predict in vivo biliary excretion.

Federico Colombo1, Catherine Armstrong, Jianmin Duan, Nathalie Rioux.   

Abstract

Prediction of biliary excretion is a challenge for drug discovery scientists due to the lack of in vitro assays. This study explores the possibility of establishing a simple assay to predict in vivo biliary excretion via the mrp2 transport system. In vitro mrp2 activity was determined by measuring the ATP-dependent uptake of 5(6)-carboxy-2',7'-dichlorofluorescein (CDCF) in canalicular plasma membrane vesicles (cLPM) from rat livers. The CDCF uptake was time- and concentration-dependent (K(m) of 2.2 ± 0.3 µM and V(max) of 115 ± 26 pmol/mg/min) and strongly inhibited by the mrp2 inhibitors, benzbromarone, MK-571, and cyclosporine A, with IC(50) values ≤ 1.1 µM. Low inhibition of CDCF uptake by taurocholate (BSEP inhibitor; 57 µM) and digoxin (P-gp inhibitor; 101 µM) demonstrated assay specificity towards mrp2. A highly significant correlation (r(2) = 0.959) between the in vitro IC(50) values from the described mrp2 assay and in vivo biliary excretion in rats was observed using 10 literature compounds. This study demonstrated, for the first time, that a high throughput assay could be established with the capability of predicting biliary excretion in the rat using CDCF as a substrate.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21961530     DOI: 10.3109/00498254.2011.614021

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  2 in total

1.  In Vitro Transport Activity and Trafficking of MRP2/ABCC2 Polymorphic Variants.

Authors:  Xia Wen; Melanie S Joy; Lauren M Aleksunes
Journal:  Pharm Res       Date:  2017-04-12       Impact factor: 4.200

2.  Bacterial β-glucuronidase inhibition protects mice against enteropathy induced by indomethacin, ketoprofen or diclofenac: mode of action and pharmacokinetics.

Authors:  Kyle S Saitta; Carmen Zhang; Kang Kwang Lee; Kazunori Fujimoto; Matthew R Redinbo; Urs A Boelsterli
Journal:  Xenobiotica       Date:  2013-07-05       Impact factor: 1.908

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.